Multi-analyte analysis of saliva biomarkers as predictors of periodontal and pre-implant disease
AssigneesThe Regents of the University of Michigan, Sandia National Laboratories
InventorsThomas Braun, William V. Giannobile, Amy E. Herr, Anup K. Singh, Charlie Shelburne
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of measuring biomarkers to determine the probability of a periodontal and/or peri-implant disease. More specifically, the invention provides a panel of biomarkers that, when used in combination, can allow determination of the probability of a periodontal and/or peri-implant disease state with extremely high accuracy.
Claims24
A diagnostic method to determine probability of an oral disease state comprising
- (a) determining the levels of two or more biomarkers in a sample collected from a first individual, wherein a first biomarker is a bone-specific marker and a second biomarker is a plaque biofilm pathogen marker, said levels of said two or more biomarkers indicating the probability of said oral disease state, wherein the first biomarker is not type I collagen pyridinoline cross-linked telopeptide (ICTP);
- wherein elevated levels of said two or more biomarkers from said first individual compared to levels of identical biomarkers from a second, healthy individual, or compared to biomarker levels of said first individual measured at an earlier time point are indicative of occurrence of oral disease in said first individual with a probability of diagnosing the disease state equal to or greater than 70%;
- and
- (b) treating said oral disease by administering an amount of a therapeutic or prophylactic composition sufficient to reduce activity of said two or more biomarkers.
A diagnostic method to determine probability of an oral disease state comprising the step of determining the levels of two or more biomarkers in a sample collected from an individual, wherein a first biomarker is a bone-specific marker and a second biomarker is a plaque biofilm pathogen marker, said levels of said two or more biomarkers indicating the probability of said oral disease state, wherein the first biomarker is not type I collagen pyridinoline cross-linked telopeptide (ICTP);
- wherein said method determines effectiveness of oral disease treatment, wherein said levels of said two or more biomarkers are indicative of effective oral disease treatment if said levels of said two or more biomarkers from said individual are decreased compared to levels of identical biomarkers from the individual measured at an earlier time point;
- and
- wherein decreased levels of said two or more biomarkers are indicative of effective oral disease treatment in said individual with a probability equal to or greater than 70%, and
- wherein increased levels of said two or more biomarkers in said individual compared to levels of identical biomarkers from the individual measured at an earlier time point are indicative of ineffective oral disease treatment, and the method then further comprises the step of treating said oral disease by administering an amount of a therapeutic composition to reduce activity of said two or more biomarkers.
Dependencies are inferred from the claim text.